• 1. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 2. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 3. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 4. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 5. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Amino fatty acids
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty acids and conjugates Amino fatty acids

Recent Advances in the Study of (2E)-4-aminopent-2-enoic acid (CAS: 69202-97-7)

The compound (2E)-4-aminopent-2-enoic acid (CAS: 69202-97-7) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural properties and potential therapeutic applications. This research brief aims to summarize the latest findings related to this compound, focusing on its synthesis, biological activity, and potential applications in drug development.

Recent studies have highlighted the role of (2E)-4-aminopent-2-enoic acid as a key intermediate in the synthesis of various bioactive molecules. Its unsaturated backbone and amino functionality make it a versatile building block for the construction of more complex structures. Researchers have explored its utility in the development of enzyme inhibitors, particularly those targeting amino acid metabolism pathways. The compound's ability to mimic natural amino acids while introducing structural variations has opened new avenues for the design of novel therapeutics.

In terms of synthesis, several innovative approaches have been reported in the past year. A study published in the Journal of Medicinal Chemistry demonstrated an efficient asymmetric synthesis route for (2E)-4-aminopent-2-enoic acid, achieving high enantiomeric purity (>99% ee) through a novel catalytic system. This advancement is particularly significant as it addresses previous challenges in obtaining optically pure forms of the compound, which is crucial for its biological applications.

From a pharmacological perspective, recent in vitro studies have revealed promising activity of (2E)-4-aminopent-2-enoic acid derivatives against various cancer cell lines. The mechanism of action appears to involve interference with glutamine metabolism, a pathway that many cancer cells rely on for growth and proliferation. These findings were further supported by molecular docking studies showing strong interactions between the compound and key enzymes in the glutaminase pathway.

Another significant development comes from neuropharmacology research, where (2E)-4-aminopent-2-enoic acid has shown potential as a modulator of neurotransmitter systems. Animal studies have demonstrated its ability to cross the blood-brain barrier and exhibit neuroprotective effects in models of neurodegenerative diseases. These properties are attributed to its structural similarity to endogenous neurotransmitters while possessing enhanced metabolic stability.

Looking forward, the pharmaceutical industry is showing increasing interest in (2E)-4-aminopent-2-enoic acid as a scaffold for drug discovery. Several patent applications filed in the past year indicate its potential application in developing treatments for metabolic disorders, neurological conditions, and certain types of cancer. However, researchers caution that more extensive preclinical studies are needed to fully evaluate its safety profile and therapeutic potential.

In conclusion, (2E)-4-aminopent-2-enoic acid (CAS: 69202-97-7) represents an exciting area of research in chemical biology and medicinal chemistry. The recent advances in its synthesis and biological evaluation have positioned it as a promising candidate for further drug development efforts. Future research directions likely include structure-activity relationship studies to optimize its pharmacological properties and investigations into its potential synergistic effects with existing therapeutic agents.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)